Severe obesity in U.S. children has more than tripled since 2008
Roughly 23% of all children were obese in 2023, up from 19% in 2008, according to the survey published this month in JAMA Network Open. Additionally, more than 1% of children between the ages of 2 and 18 had 'extremely severe obesity' — a 250% increase from the start of the study, the researchers from UC San Diego found.
Phillipp Hartmann, the study's corresponding author, said he hopes the results lead to more trials that test the benefits of powerful weight loss drugs called GLP-1s for children and adolescents with severe obesity.
'It might be reasonable in those patients to have the weight loss medications very early,' he said in an interview.
Medical professionals may be open to broadening the use of the popular weight loss drugs to treat obesity and diabetes in ever-younger patients. The Food and Drug Administration has approved only semaglutide, the main ingredient in Novo Nordisk's Ozempic and Wegovy, for children 12 and older. But weight-loss medicines have been tested on kids as young as 6.
Severe obesity also came with a higher risk of other health complications, such prediabetes and diabetes, severe insulin resistance and metabolic syndrome — a cluster of conditions that can increase the chance of heart disease and stroke.
The results were based on information from more than 25,000 children gathered as part of the National Health and Nutrition Examination Survey, which is managed by the Centers for Disease Control and Prevention and the National Center for Health Statistics.
Amponsah writes for Bloomberg.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
an hour ago
- The Hill
Weight loss drugs may boost testosterone in men, study finds
GLP-1 weight loss medications like Ozempic and Wegovy could increase testosterone levels and help prevent erectile dysfunction in men, according to a new study. While more data is needed, researchers from St. Louis University Hospital saw significant increases in testosterone levels for men with obesity or Type 2 diabetes while taking GLP-1 medication. Men who experience obesity or have Type 2 diabetes often have lower levels of testosterone, which can impact sexual function, muscle mass and bone density. In the study, the testosterone levels of 110 adult men with obesity or Type 2 diabetes, who were taking GLP-1 medications and not taking testosterone therapies, were analyzed before and throughout 18 months of treatment. The average age in the study was 54. The study showed that in addition to weight loss, 'the proportion of men with normal levels of both total and free testosterone rose from 53% to 77%,' according to the Endocrine Society. 'Our study is among the first to provide compelling evidence that low testosterone can be reversed with the use of commonly prescribed anti-obesity medications,' said Dr. Shellsea Portillo Canales, an endocrinologist at St. Louis University Hospital. The study's findings also came with certain limitations. The study was retrospective, meaning researchers analyzed electronic health records rather than conducting a clinical trial. In addition, the testosterone levels of men included in the study were not measured after they stopped taking the GLP-1 medications. 'If weight is regained, testosterone levels could potentially drop again,' Portillo told NBC News. GLP-1 medications have exploded in popularity due to their efficacy in controlling blood glucose and weight management, according to UChicago Medicine. The results of the study were presented at ENDO 2025, the Endocrine Society's yearly meeting in San Francisco.
Boston Globe
an hour ago
- Boston Globe
Canceled HIV research in R.I. is reinstated, but fears persist about DEI crackdown
The order from US District Judge William Young in Massachusetts was narrow, reinstating nearly 900 grants awarded to the plaintiffs, not all of the thousands of grants canceled by NIH so far this year. Young called DEI an 'undefined enemy‚" and said the Trump administration's 'blacklisting' of certain topics 'has absolutely nothing to do with the promotion of science or research.' Get Rhode Island News Alerts Sign up to get breaking news and interesting stories from Rhode Island in your inbox each weekday. Enter Email Sign Up The Trump administration is appealing the ruling, and Advertisement 'We feel like we're tippy-toeing around,' said Nunn, who leads the Rhode Island Public Health Institute. 'The backbone of the field is steadfast pursuit of the truth. People are trying to find workarounds where they don't have to compromise the integrity of their science.' Advertisement Nunn said she renewed her membership to the American Public Health Association in order to ensure she'd be included in the lawsuit. Despite DEI concerns, she plans to continue enrolling gay Black and Hispanic men in her study, which will include 300 patients in Rhode Island, Mississippi, and Washington, D.C. Black and Hispanic men who have sex with other men contract HIV at The study was just getting underway, with 20 patients enrolled, when the work was shut down by the NIH in March. While Nunn's clinic in Providence did not do any layoffs, the clinic in Mississippi — Express Personal Health — shut down, and the D.C. clinic laid off staff. The four-month funding flip-flop could delay the results of the study by two years, Nunn said, depending on how quickly the researchers can rehire and train new staff. The researchers will also need to find a new clinic in Mississippi. The patients — 100 each in Rhode Island, Mississippi, and D.C. — will then be followed for a year as they take Pre-Exposure Prophylaxis, or PrEP, to The protocol that's being studied is the use of a patient navigator for 'aggressive case management.' That person will help the patient navigate costs, insurance, transportation to the clinic, dealing with homophobia and other barriers to staying on PrEP, which can be taken as a pill or a shot. The study's delay means 'the science is aging on the vine,' Nunn said, as new HIV prevention drugs are rolled out. 'The very thing that we're studying might very well be obsolete by the time we're able to reenroll all of this.' Advertisement Dr. Amy Nunn, executive director of the Rhode Island Public Health Institute, in a patient room at Open Door Health, an HIV clinic in Providence, R.I. Patients will be seen here for her HIV study that has been reinstated following a lawsuit against the Trump administration. Jonathan Wiggs/Globe Staff The hundreds of reinstated grants include titles that reference race and gender, such as a study of cervical cancer screening rates in Latina women, alcohol use among transgender youth, aggressive breast cancer rates in Black and Latina women, and multiple HIV/AIDs studies involving LGBTQ patients. 'Many of these grants got swept up almost incidentally by the particular language that they used,' said Peter Lurie, the president of the Center of Science in the Public Interest, which joined the lawsuit. 'There was an arbitrary quality to the whole thing.' Lurie said blocking scientists from studying racial disparities in public health outcomes will hurt all Americans, not just the people in the affected groups. 'A very high question for American public health is why these racial disparities continue to exist,' Lurie said. 'We all lose in terms of questions not asked, answers not generated, and opportunities for saving lives not implemented.' The Trump administration is not backing down from its stance on DEI, even as it restores the funding. The reinstatement letters from the NIH sent to scientists this month include a condition that they must comply with Trump's executive order on 'biological truth,' which rescinded federal recognition of transgender identity, along with Title VI of the Civil Rights Act of 1964, which prohibits discrimination based on race, color and national origin. Kenneth Parreno, an attorney for the plaintiffs, said he was told by Trump administration lawyers that new letters would be sent out without those terms. But Andrew Nixon, a spokesperson for the Department of Health and Human Services, said Wednesday the administration 'stands by its decision to end funding for research that prioritized ideological agendas over scientific rigor and meaningful outcomes for the American people.' Advertisement 'HHS is committed to ensuring that taxpayer dollars support programs rooted in evidence-based practices and gold standard science — not driven by divisive DEI mandates or gender ideology," Nixon said in any email to the Globe. The Trump administration's appeal is pending before the First Circuit Court of Appeals in Boston. A motion for a stay of Young's decision was denied, and the Trump administration is appealing that ruling to the US Supreme Court. The ongoing push to remove DEI from science has created fear in the scientific community, which relies on federal funding to conduct its research and make payroll. 'Scientific morale has taken a big hit,' Nunn said. 'People are apprehensive.' Indeed, major research institutions have faced mass funding cuts from the federal government since Trump took office. Brown University, the largest research institution in Rhode Island, had more than $500 million frozen until it In exchange for the research dollars to be released, Brown agreed not to engage in racial discrimination in admissions or university programming, and will provide access to admissions data to the federal government so it can assess compliance. The university also agreed not to perform any gender-affirming surgeries and to adopt Trump's definitions of a male and female in the 'biological truth' executive order. While some have avoided speaking out, fearing further funding cuts, Nunn said she felt a 'moral and ethical duty' to do so. Advertisement 'We have to dissent,' Nunn said. 'Scientific discovery around the world hangs in the balance.' Steph Machado can be reached at
Business Wire
3 hours ago
- Business Wire
Aetna Marks 3 Years of Type 2 Diabetes Reversal through Virta Health, Thousands See Results
PHOENIX--(BUSINESS WIRE)-- Banner|Aetna, a joint venture health plan owned by Banner Health and Aetna, a CVS Health company, celebrates three years of investing in members by offering an evidence-based diabetes reversal initiative. In 2022, the insurer was an early adopter of Virta Health for diabetes reversal – the process of reducing blood glucose levels to below the threshold used to diagnose diabetes. 1 Since then, the program enrollment has grown 290% and thousands of members have achieved sustainable health transformations while reducing their need for expensive weight loss medications, like Wegovy and Ozempic. 2 The flexible app-based program uses a virtual model to address the root cause of metabolic disease through individualized nutrition plans that fit members' unique lifestyles, cultural background, dietary preferences, and budget. Thanks to the personalized approach and one-on-one expert support, participants are experiencing significant and lasting outcomes. Recent data shows that Banner|Aetna members saw meaningful metabolic health improvements after 365 days of program enrollment, including the following. Blood sugar reduction: On average, members saw a 0.97% reduction in A1C blood sugar levels. 3 Every one-point decrease in A1C reduces the risk of long-term diabetes complications by up to 40%. Prescription reduction: Members eliminated 57% of diabetes medications (excluding metformin), including a 66% reduction in insulin dosages. Of those on insulin, 44% eliminated it completely. 4 Clinically significant weight loss: 61% of members experienced clinically significant weight loss (5% or more); on average, members lost 8% of their body weight. 5 Clinically significant weight loss can lead to better sleep, reduced inflammation, improved blood pressure, reduced risk of heart disease and positive impacts on arthritis and fatty liver disease. In addition to the diabetes reversal program demonstrating outstanding clinical results, Banner|Aetna's omnichannel outreach approach achieves 3x higher member engagement compared to industry averages. 6 Through deep integration with Banner Health—one of Banner|Aetna's parent companies and Arizona's largest healthcare delivery system—the insurer leverages the Banner Health clinical and care management teams to refer eligible members into a diabetes management program. 'The U.S. is facing a metabolic disease crisis. One in 10 people lives with diabetes, and most have type 2. One in three has prediabetes,' explains Ed Clarke, MD, Banner|Aetna Medical Director and VP, CMO Banner Plans & Networks. 'These conditions take a toll on the physical, emotional and financial health of millions of people in Arizona. That's why Banner|Aetna collaborated with Virta to offer members a holistic, non-pharmacological approach that puts disease reversal within reach. The feedback from members who have completed the program shows its dramatic impact on their lives. Not only do they gain a better understanding of disease management, but more importantly how they can take control health of their health.' The results speak for themselves as members are achieving notable clinical outcomes helping them reclaim their lives, while also having a positive effect that ripples out to their families and the broader community. For Banner|Aetna member Shelby*, learning to use food as medicine has led to 'amazing' changes in her life, including increased energy, better sleep, and weight loss. 'I have learned how my body reacts to a wide array of foods and what I can eat to help it flourish,' she explains. 'I am very thankful for the support my coach provides every step of the way, and her encouragement that I am worth the hard work.' Banner|Aetna currently offers type 2 diabetes reversal to eligible members of fully insured and Administrative Services Only groups. Additionally, Banner|Aetna self-funded employer groups can access Virta's prediabetes and obesity reversal offerings, which use the same innovative care model. About Banner|Aetna Banner|Aetna is a health insurance company focusing on bettering member outcomes at a lower cost, all while improving the overall member experience for employers and consumers in Arizona. The collaboration combines Banner Health's quality, local providers and delivery systems with Aetna's health-plan experience, care management and health information technology. Banner|Aetna is the brand name used for products and services provided by Banner Health and Aetna Health Insurance Company and Banner Health and Aetna Health Plan Inc. For more information about Banner|Aetna, visit About Banner Health Banner Health is one of the largest, secular nonprofit health care systems in the country. In addition to 33 hospitals, Banner also operates an academic medicine division, Banner – University Medicine, and Banner MD Anderson Cancer Center, a partnership with one of the world's leading cancer programs, MD Anderson Cancer Center. Banner's array of services includes a health insurance division, employed physician groups, outpatient surgery centers, urgent care locations, home care and hospice services, retail pharmacies, stand-alone imaging centers, physical therapy and rehabilitation, behavioral health services, a research division and a nursing registry. To make health care easier, 100% of Banner-employed doctors are available for virtual visits and patients may also reserve spots at Banner Urgent Care locations and can book appointments online with many Banner-employed doctors. Headquartered in Arizona, Banner Health also has locations in California, Colorado, Nebraska, Nevada and Wyoming. For more information, visit About CVS Health CVS Health is a leading health solutions company building a world of health around every consumer, wherever they are. As of March 31, 2025, the Company had more than 9,000 retail pharmacy locations, more than 1,000 walk-in and primary care medical clinics, a leading pharmacy benefits manager with approximately 88 million plan members, and a dedicated senior pharmacy care business serving more than 800,000 patients per year. The Company also serves an estimated more than 37 million people through traditional, voluntary and consumer-directed health insurance products and related services, including highly rated Medicare Advantage offerings and a leading standalone Medicare Part D prescription drug plan. The Company's integrated model uses personalized, technology driven services to connect people to simply better health, increasing access to quality care, delivering better outcomes, and lowering overall costs. 1 Riddle MC, Cefalu WT, Evans PH et al. Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. Diabetes Care 1 October 2021; 44 (10): 2438–2444. 2 Virta Health & Banner|Aetna Clinical Outcomes. March 31, 2025. 3 Virta Health & Banner|Aetna Clinical Outcomes. February 27, 2025. 4 Ibid. 5 Ibid. 6 Engagement data reported by Virta Health. January 2023-May 2025. * The member's uncompensated testimonial reflects the enrollee's experience with Virta Health.
